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Abstract
Background
Because of the potential mutagenic effects of chemo- and radiotherapy, there is concern
regarding increased risk of congenital malformations (CMs) among children of fathers with
cancer. Previous register studies indicate increased CM risk among children conceived
after paternal cancer but lack data on oncological treatment. Increased CM risk was recently
reported in children born before paternal cancer. This study aims to investigate whether
anti-neoplastic treatment for testicular germ-cell cancer (TGCC) implies additional CM risk.
Methods and findings
In this nationwide register study, all singletons born in Sweden 1994–2014 (n = 2,027,997)
were included. Paternal TGCC diagnoses (n = 2,380), anti-neoplastic treatment, and off-
spring CMs were gathered from the Swedish Norwegian Testicular Cancer Group (SWENO-
TECA) and the Swedish Medical Birth Register. Children were grouped based on +/-
paternal TGCC; treatment regimen: surveillance (n = 1,340), chemotherapy (n = 2,533), or
radiotherapy (n = 360); and according to time of conception: pre- (n = 2,770) or post-treat-
ment (n = 1,437). Odds ratios (ORs) for CMs were calculated using logistic regression with
adjustment for parental ages, maternal body mass index (BMI), and maternal smoking. Chil-
dren conceived before a specific treatment acted as reference for children conceived after
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the same treatment. Among children fathered by men with TGCC (n = 4,207), 184 had a
CM. The risk of malformations was higher among children of fathers with TGCC compared
with children fathered by men without TGCC (OR 1.28, 95% confidence interval [CI] 1.19–
1.38, p = 0.001, 4.4% versus 3.5%). However, no additional risk increase was associated
with oncological treatment when comparing post-treatment–to pretreatment-conceived chil-
dren (chemotherapy, OR = 0.82, 95% CI 0.54–1.25, p = 0.37, 4.1% versus 4.6%; radiother-
apy, OR = 1.01, 95% CI 0.25–4.12, p = 0.98, 3.2% versus 3.0%). Study limitations include
lack of data on use of cryopreserved or donor sperm and on seminoma patients for the
period 1995–2000—both tending to decrease the difference between the groups with TGCC
and without TGCC. Furthermore, the power of analyses on chemotherapy intensity and
radiotherapy was limited.
Conclusions
No additional increased risk of CMs was observed in children of men with TGCC treated
with radio- or chemotherapy. However, paternal TGCC per se was associated with modestly
increased risk for offspring malformations. Clinically, this information can reassure con-
cerned patients.
Author summary
Why was this study done?
• Chemotherapy and radiotherapy have both been shown to cause mutations and genetic
damage in animal studies, leading to fears that men being treated with these therapies
might be more prone to have children with genetic diseases and birth defects.
• This study investigates whether receiving treatment for testicular cancer, being the most
common cancer among young men (in child-having ages), leads to a higher risk of
fathering a child with a birth defect.
What did the researchers do and find?
• By accessing data from Swedish national registries, we gathered data on more than 2
million newborns and their fathers. Among them, 2,380 fathers had testicular cancer
and they had, in total, 4,207 children.
• When comparing the children conceived after the father received cancer treatment to
the children born before treatment, we could not find any evidence showing that che-
motherapy or radiotherapy leads to an increased risk of birth defects.
• We did see that there was, irrespectively of cancer treatment, a small risk increase asso-
ciated with the fathers’ testicular cancer itself, meaning that men with testicular cancer
have an approximately 30% higher relative risk of having a child with a birth defect (an
increase from 3.5% to 4.4%).
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What do these findings mean?
• There was no risk increase due to cancer therapies.
• The risk increase detected was associated with testicular cancer. However, this risk
increase is very small and relates to rare conditions.
• Because the risk increase is small, we therefore do not consider this cause for concern
and wish this reassuring information to be passed on to patients.
Introduction
Children fathered by men treated for cancer might be at higher risk for congenital malforma-
tions (CMs) due to the mutagenic effects of irradiation and cytotoxic drugs. Adverse effects of
oncological treatments on germ cells have been described in animal [1,2] and human studies
[3–5]. Furthermore, a Danish–Swedish population-based study has shown that children con-
ceived after a father’s cancer diagnosis have a slight increase in prevalence of severe CM [6]. A
possible pathway for the increased malformations risk might be detrimental genetic alterations
of germline DNA by oncological treatment, resulting in more frequent CMs in children con-
ceived after paternal oncological treatment.
There are indications that the excess risk of CMs for children born to fathers with cancer
might be due to the malignancy per se rather than to the anticancer treatment. A Swedish pop-
ulation-based register study including 2.1 million children investigated the CM risk for chil-
dren conceived prior to and after paternal cancer diagnosis and found those two groups to
have an increased risk of malformations of about the same magnitude [7]. This study, when
stratifying by cancer type, specifically showed that testicular cancer is one of the malignancies
associated with increased CM risk in children conceived prior to paternal cancer diagnosis.
Testicular cancer is the most common cancer in young men, and approximately 97% of tes-
ticular cancers are derived from germ cells, so-called testicular germ-cell cancer (TGCC).
TGCC has a 15-year survival of about 95% [8], and most patients will father children before or
after the diagnosis. Among those TGCC patients who are childless at the time of cancer diag-
nosis, 77% express a wish for future fatherhood, despite some having anxieties about the
potential detrimental health effects of cancer therapy on the health of their offspring [9].
Previous studies have lacked treatment data, making estimation of the possible additional
effects of specific cancer therapies impossible. Opportunely, the Swedish Norwegian Testicular
Cancer Group (SWENOTECA) registry includes treatment data on nonseminoma patients
treated since 1995 and seminoma patients since 2000 for all Swedish and Norwegian TGCC
patients. The main aim of this study was, by linking Swedish national registries to SWENO-
TECA, to investigate whether anti-neoplastic therapy implies any additional malformation
risk in children fathered by men treated for TGCC. The secondary aim was to investigate
whether TCGG per se is associated with risk of CM.
Methods
Study design and data sources
The cohort was defined as all newborns born alive and registered in the Swedish Medical Birth
Register 1994–2014 (n = 2,108,569). Data from the Swedish Total Population Register and the
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Swedish Multigenerational Register allowed identification of their parents. Every individual in
the cohort was given a unique serial number linked to their Swedish Personal Identity Num-
ber. These identification numbers were sent to the Swedish National Board of Health and Wel-
fare, which supplied excerpts from national registries. To maintain anonymity, the Personal
Identity Numbers were redacted by the Swedish National Board of Health and Welfare. Chil-
dren with missing paternal serial numbers (n = 19,970) and twins and other multiples (n =
60,602) were excluded. After these exclusions, 2,027,997 singletons, 1,167,665 fathers, and
1,166,462 mothers remained in the cohort (Fig 1).
Perinatal and parental attributes for all children were obtained from Swedish Medical Birth
Register, the Swedish National Quality Register for Assisted Reproduction, and the Swedish
Register of Education. Paternal TGCC diagnoses and treatment data were retrieved from the
Swedish part of SWENOTECA, which holds information on clinical stage, treatment, and
Fig 1. Definition of the study population, register linking, and subgrouping. �Numbers do not sum because there is overlap between groups. TGCC,
testicular germ-cell cancer.
https://doi.org/10.1371/journal.pmed.1002816.g001
Testicular cancer therapy and offspring malformation risk
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002816 June 4, 2019 4 / 14
follow-up for up to 10 years after diagnosis for nonseminoma patients since 1995 and semi-
noma patients since 2000. All Swedish cancer centers report to the SWENOTECA database,
which is then cross-checked with the Swedish Cancer Registry every third month through the
personal national registration numbers assigned to each resident in Sweden at birth or perma-
nent residency. The completeness of the Swedish Cancer Registry is almost 100% [10]. The
analysis plan is presented in S1 Text. The regional ethical boards of Lund and Stockholm
approved this study (No: 2015/670 and 2016/2562-31/2).
CMs
The classification of CM according to the International Classification of Diseases (ICD) codes
has been described previously [7]. Abridgedly, the definitions used for all congenital abnor-
malities were ICD-9-SE 740–759 and ICD-10-SE Q00-Q99. Major malformations were classi-
fied following the coding guide of European Surveillance of Congenital Anomalies.
Groups according to paternal oncological treatment
The grouping of the children was according to whether the child was conceived prior to or
after the father’s TGCC diagnosis by using the gestational length for the child to estimate con-
ception date. Both the children conceived prior to and after paternal TGCC diagnosis were
subgrouped according to the fathers’ oncological treatment regimen into the following groups:
chemotherapy, radiotherapy, and surgery only (surveillance). Chemotherapy regimens and
number of cycles were defined according to the SWENOTECA cancer care protocols. Any
dose of radiotherapy was counted as exposure.
Statistical analyses
Risk estimates for congenital malformations were evaluated using a multivariable binary logis-
tic regression model, yielding odds ratios (ORs) with 95% confidence intervals (CIs). The
model was adjusted for the following covariates: maternal age at childbirth (continuous),
paternal age at offspring birth (continuous), maternal body mass index (BMI) (categorical:
<20,�20 to<25,�25 to<30,�30 to<35,�35 kg/m2), and self-reported maternal smoking
at first prenatal visit (categorical: nonsmoker, 1–9 cigarettes per day,�10 cigarettes per day).
These covariates were chosen because they have been previously shown to affect birth out-
comes [11–13].
Multiple imputation by fully conditional specification was used to handle cases with miss-
ing data, creating 5 imputed data sets. All the variables and outcomes in the regression models
were used as predictors to impute missing values for maternal weight, height, age at childbirth,
and maternal smoking during pregnancy. For children born to fathers with TGCC and miss-
ing gestational length (n = 5), the median value (280 days) of the cohort was used. Other covar-
iates and outcomes in the model did not have missing data.
Analyses investigating the effect of paternal anti-TGCC treatment were performed to
ensure comparability between groups. The type of oncological treatment given relates to the
subtype of TGCC. Therefore, in order to adjust for the potential effect of aggressiveness of the
paternal disease, children born to fathers who would, after the child’s conception, be treated
with chemotherapy acted as the reference for children conceived after the father was exposed
to chemotherapy. Similarly, the children born to fathers who would, after the offspring’s con-
ception, receive radiation were the reference for the children born after radiation.
Because detrimental effects of chemotherapy on the offspring of treated patients might only
be apparent at high treatment doses, a subanalysis was conducted in which the children were
Testicular cancer therapy and offspring malformation risk
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stratified according to the number of cycles of chemotherapy (1–2; 3–4; 5+) given to the father
and if the children were conceived before or after paternal diagnosis.
The children to fathers were split into two groups according to whether they were con-
ceived before (reference group) or after the fathers’ TGCC diagnosis. These two groups were
compared to see whether the children conceived after diagnosis had an increased risk of mal-
formations due to any form of treatment.
It has been previously reported that children born to fathers with TGCC have an increased
risk of birth defects, even when the child is conceived prior to paternal oncological treatment
[7]. Therefore, all the children to fathers with TGCC were compared to the children of fathers
without TGCC (reference) to evaluate whether there was a difference in risk for congenital
malformations. Separate sensitivity analyses excluded children conceived by assisted reproduc-
tion techniques (ARTs) and children conceived to fathers with a cancer diagnosis other than
TGCC.
All statistical analyses were performed by the first author using SPSS version 25 (IBM Corp,
Armonk, NY, USA). Statistical analyses were two-sided. Risk estimates were pooled from mul-
tiple imputed values, with p< 0.05 considered statistically significant.
Results
Study population
Overall, 2,027,997 children were included in the study cohort (Fig 1). Of the total number
included, 4,207 (0.2%) had fathers diagnosed with TGCC. Of these, 2,770 (65.8%) were con-
ceived prior to and 1,437 (34.2%) were conceived after the TGCC diagnosis. The distribution
of children according to time of paternal TGCC diagnosis showing other parental characteris-
tics and birth outcomes is presented in Table 1.
The most common treatment was chemotherapy, and the largest group of children were
those fathered by men treated with chemotherapy (total n = 2,533, 60.2%, Table 2). The distri-
bution of fathers according to treatment modality and intensity is given in Table 3.
CMs in relation to paternal TGCC treatment
When comparing the children conceived after particular anti-TGCC treatment regimen with
the children conceived prior to the same regimen, there was no statistically significant increased
risk after radiotherapy (all malformations: OR = 1.01, 95% CI = 0.25–4.12, p = 0.98, 3.2% versus
3.0%; major malformations: OR = 1.37, 95% CI = 0.27–7.05, p = 0.70, 2.5% versus 2.0%) or fol-
lowing chemotherapy (all malformations: OR = 0.82, 95% CI = 0.54–1.25, p = 0.37, 4.1% versus
4.6%; major malformations: OR = 1.01, 95% CI = 0.62–1.65, p = 0.97, 3.1% versus 3.1%).
The frequency of CMs according to the number of chemotherapy cycles the father was
treated with is given in S1 Table. Although this analysis has low statistical power, in 5 of 6 sub-
categories, the OR of malformation risk was below 1 for the post-treatment children as com-
pared to the prediagnosis group.
The children conceived after paternal TGCC diagnosis, as compared to those conceived
before paternal TGCC, showed no risk difference either for all or for major malformations
(OR = 0.88, 95% CI = 0.63–1.22, p = 0.43, 4.1% versus 4.5% and OR = 1.03, 95% CI = 0.69–
1.53, p = 0.88, 2.9% versus 2.9%, respectively).
CMs in children of TGCC men
Children to fathers with TGCC had a statistically significantly increased risk for both all and
major CMs as compared to children born to fathers without TGCC (OR = 1.28, 95%
Testicular cancer therapy and offspring malformation risk
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CI = 1.19–1.38, p = 0.001, 4.4% versus 3.5% and OR = 1.36, 95% CI = 1.24–1.49, p< 0.001,
2.9% versus 2.2%, respectively; Fig 2).
In the sensitivity analyses excluding children conceived by assisted reproduction, we found
negligible differences in risk estimates (all malformations: OR = 1.25, 95% CI = 1.16–1.36,
p = 0.004, 4.3% versus 3.4%; major malformations: OR = 1.37, 95% CI = 1.25–1.51, p< 0.001,
Table 1. The distribution of children according to paternal TGCC diagnosis with parental characteristics and birth outcomes.
Characteristic No paternal TGCC Conceived prior to paternal TGCC
diagnosis
Conceived after paternal TGCC
diagnosis
Total no. of children 2,023,790 2,770 1,437
Parental characteristics
Maternal age at offspring birth, years, mean (SD) 29.9 (5.1) 29.0 (4.9) 31.1 (4.6)
Maternal BMI at early pregnancy, kg/m2, mean (SD) 24.4 (4.4) 24.2 (4.2) 24.5 (4.6)
Paternal age at offspring birth, years, mean (SD) 32.8 (6.2) 30.9 (4.9) 33.8 (4.8)
Nonsmoking mothers early in pregnancy, no. (%) 1,826,916 (90.3) 2,466.6 (89.0) 1,372 (95.5)
Mothers smoking 1–9 cigarettes per day, no. (%) 139,791.2 (6.9) 210.8 (7.6) 47.2 (3.3)
Mothers smoking more than 10 cigarettes per day, no.
(%)
57,082.8 (2.8) 92.6 (3.3) 17.8 (1.2)
Mode of conception
Assisted 42,521 (2.1) 71 (2.6) 201 (14.0)
Birth characteristics
Sex, no. (%)
Male 1,040,460 (51.4)� 1,428 (51.6) 723 (50.3)
Female 983,324 (48.6)� 1,342 (48.4) 714 (49.7)
CMs
All congenital abnormalities, no. (%) 69,920 (3.5) 125 (4.5) 59 (4.1)
Major congenital abnormalities, no. (%) 43,714 (2.2) 80 (2.9) 42 (2.9)
Values are pooled over 5 imputed data sets.
�Excluding 6 children for whom sex was missing.
Abbreviations: BMI, body mass index; CM, congenital malformation; no., number; SD, standard deviation; TGCC, testicular germ-cell cancer.
https://doi.org/10.1371/journal.pmed.1002816.t001
Table 2. Parental and perinatal characteristics for groupings based on when conception occurred in relation to paternal treatment regimen.
Characteristic Paternal treatment regimen
Surgery only Chemotherapy Radiotherapy
Conceived before Conceived after Conceived before Conceived after Conceived before Conceived after
Total no. of children 947 393 1,639 894 203 157
Mode of conception
Assisted 29 (3.1) 39 (9.9) 40 (2.4) 139 (15.5) 4 (2.0) 26 (16.6)
Birth characteristics
Sex, no. (%)
Male 504 (53.2) 196 (49.9) 838 (51.1) 444 (49.7) 98 (48.3) 86 (54.8)
Female 443 (46.8) 197 (50.1) 801 (48.9) 450 (50.3) 105 (51.7) 71 (45.2)
CMs
All congenital abnormalities, no. (%) 45 (4.8) 18 (4.6) 75 (4.6) 37 (4.1) 6 (3.0) 5 (3.2)
Major congenital abnormalities, no. (%) 27 (2.9) 11 (2.8) 50 (3.1) 28 (3.1) 4 (2.0) 4 (2.5)
There were 19 children conceived to fathers prior to treatment with both chemotherapy and radiotherapy; among them, one had a major malformation. Similarly, 7
children were conceived after both treatment modalities, with one major malformation among them. Abbreviations: CM, congenital malformation; no., number.
https://doi.org/10.1371/journal.pmed.1002816.t002
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Table 3. Distribution of fathers according to cancer and oncological treatment.
Paternal TGCC Seminoma� Nonseminoma† All TGCC
Total no. of fathers (%) 1,308 (55.0) 1,072 (45.0) 2,380
Age at diagnosis, years, mean (SD) 37.3 (6.9) 31.9 (7.2) 34.9 (7.5)
Treatment modality
Surgery only, no. of fathers (%) 477 (61.8) 295 (38.2) 772
Age at diagnosis, years, mean (SD) 37.8 (6.9) 33.0 (7.9) 35.9 (7.7)
Chemotherapy‡
No. of fathers (%) 638 (45.2) 774 (54.4) 1,412
Age at diagnosis, years, mean (SD) 37.8 (6.9) 31.4 (6.8) 34.3 (7.6)
Chemotherapy cycles, no. of fathers (%)
1–2 484 (56.3) 376 (43.7) 860
3–4 142 (29.2) 345 (70.8) 487
5+ 1 (2.2) 44 (97.8) 45
Missing data 11 (55.0) 9 (45.0) 20
Radiotherapy§
No. of fathers (%) 180 (98.9) 2 (1.1) 182
Age at diagnosis, years, mean (SD) 34.5 (5.8) 31.8 (4.2) 34.5 (5.8)
Chemotherapy and radiotherapy
No. of fathers (%) 13 (92.9) 1 (7.1) 14
Average age at diagnosis, years (SD) 36.6 (8.9) 45.0 (-) 37.2 (8.8)
�Excluding patients also having nonseminoma (patients with mixed TGCC, seminoma and nonseminoma, are included in the nonseminoma group because they receive
similar treatments under SWENOTECA cancer care protocols).
†Including patients also having seminoma.
‡Excluding patients also receiving radiotherapy.
§Excluding patients also receiving chemotherapy
Abbreviations: no., number; SD, standard deviation; SWENOTECA, the Swedish Norwegian Testicular Cancer Group; TGCC, testicular germ-cell cancer.
https://doi.org/10.1371/journal.pmed.1002816.t003
Fig 2. Forest plot of ORs and 95% CIs for risk of all and major malformations. Calculations were made according to the presence of TGCC or not and
according to before or after treatment with radiotherapy or chemotherapy. CI, confidence interval; OR, odds ratio; TGCC, testicular germ-cell cancer.
https://doi.org/10.1371/journal.pmed.1002816.g002
Testicular cancer therapy and offspring malformation risk
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002816 June 4, 2019 8 / 14
2.9% versus 2.1%). Excluding the children of fathers with non-TGCC cancer from the refer-
ence group did not change the risk estimates (OR = 1.28, 95% CI = 1.19–1.38, p = 0.001, 4.4%
versus 3.5% and OR = 1.36, 95% CI = 1.24–1.49, p< 0.001, 2.9% versus 2.2%).
Discussion
In this study, we found that children of fathers with TGCC had an approximately 30%
increased malformation risk as compared to children of fathers without TGCC. This modest
increase applied to more severe forms of malformations, as well. However, when comparing
children conceived after radio- or chemotherapy to those conceived prior to these potentially
mutagenic treatments, there was no increased risk associated with either treatment. While
very few in numbers, the same was true even for children conceived after more extensive pater-
nal chemotherapy regimens. Altogether, our results indicate that although children born to
fathers with TGCC have a significantly increased risk of all and major CMs, it is unlikely to be
due to the effects of radio- or chemotherapy.
In 2011, we published a Danish–Swedish register study lacking information on paternal
oncological treatment in which we observed that children born after paternal cancer diagnosis
had a slight increase in CM rate [6]. This study indicated that the increase could be due to fac-
tors unrelated to cancer therapy because higher rates were also observed in children fathered
by men with malignancies usually treated with surgery only. Supporting this thesis, our recent
study showed that children conceived prior to a paternal cancer diagnosis, and therefore
before treatment, were also more prone to have CM [7]. Few studies have addressed the issue
of teratogenic risk following paternal oncological treatment, and none of the studies found an
increased risk of CM [14–17]. Those studies, however, were not powered to detect small risk
increases, such as those observed in this study. Parental exposure of mice to radiation and
chemicals causes a variety of adverse effects (e.g., tumors, CMs, and embryonic deaths) in the
progeny [18]. Direct exposure to ionizing radiation has been shown to increase the risk of
childhood leukemia; however, paternal exposure has not been shown to affect the health of the
offspring [19].
The association between the germ-cell–derived TGCC and CM risk in children is quite puz-
zling. In 2001, Skakkebaek and colleagues suggested that congenital genitourinary malforma-
tions, TGCC, and male infertility are caused by a common factor present during fetal life,
being different manifestations of so-called testicular dysgenesis syndrome (TDS) [20]. Accord-
ing to the TDS hypothesis, the vast majority of testis tumors are derived from malignantly
transformed precancerous germ-cell neoplasm in situ (GCNIS) cells, which in turn originate
from mitotically arrested fetal gonocytes [21]. Although speculative, TDS could be the underly-
ing syndrome linking paternal TGCC and offspring CMs. Because TDS is believed to be caused
by a combination of environmental exposure and genetic factors in early fetal development,
the same exposures/factors might lead to suboptimal development in the whole testes. Alterna-
tively, the presence of GCNIS cells could itself be the cause of the increased risk of offspring
malformations. It is unlikely that GCNIS cells undergo spermatogonial differentiation because
of the genetic and morphological changes they exhibit. Instead, GCNIS cells, which occupy the
same niche as germ cells, might influence the surrounding spermatogonal development
through changes to the sensitive microenvironment within the seminiferous tubules. Indeed,
infertility does often precede TGCC [22], and pretreatment TGCC patients have elevated levels
of sperm DNA damage (higher DNA fragmentation index) [23], possibly due to perturbations
of the physiologically unique meiotic DNA repair pathway occurring in spermatogonia. Con-
versely, infertility and sperm DNA damage has been observed preceding other types of malig-
nancies as well. Therefore, other mechanisms might also be operating, aligning with our
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previous study showing that children conceived to men with other cancers, such as neurologi-
cal malignancies, also had an increased risk of CM [7].
Increased levels of reactive oxygen species (ROSs) have also been suggested as a possible
factor in pathogenesis of different malignancies. ROSs were shown to cause postmeiotic oxida-
tive sperm DNA damage during a phase of germ-cell development when sperms lack DNA
repair machinery [24]. Increased rates of these paternally derived DNA lesions, like single-
and double-stranded breaks, have been shown to detrimentally affect embryonic development,
rates of miscarriage, and pregnancy [25] and can ultimately lead to offspring with chromo-
somal aberrations [26]. Supporting this mechanism, our previous study indicated a 40%
increase in chromosomal malformations among children born before paternal cancer [7].
Large genomic studies have shown that around 80% of de novo mutations occurring in the
human population are derived from the paternal germline [27]. These de novo mutations
among the offspring have been linked to CMs, schizophrenia, and autism [28–30]. Genomic
studies have shown that the rate of de novo mutations that are passed on to offspring differs by
more than 2-fold between fathers [27]. This indicates that some men experience more muta-
tions in their germ cells and conceivably also in their somatic cells, possibly due to a systemic
insufficiency of DNA repair. This genomic instability might itself predispose to malignancies.
Large genome-wide association studies have identified a multitude of risk loci associated
with TGCC susceptibility. Interestingly, several of the loci identified support the TDS hypothe-
sis with developmental arrest of fetal gonocytes because the loci are involved in transcriptional
dysregulation. However, the same study suggests a multifactorial pathway might be at play
because some risk loci were involved in defective microtubule function, which can lead to
chromosomal instability [31].
Our findings have some potential clinical implications. First of all, although we find some-
what increased risk of CM in children fathered by men with TGCC, this increase is rather
modest, and this reassuring information can be passed on to patients. Furthermore, our data
do not seem to support the general assumption of increased risk of malformations in offspring
of men treated with chemotherapy. Taken altogether, our results indicate that there is no cause
for concern for men having undergone TGCC treatment regarding the health of their off-
spring. However, with 14% of the children born after TGCC treatment being conceived by
ARTs, presumably due to high levels of infertility after gonadotoxic treatments, pretreatment
sperm cryopreservation is still indicated since no tools for reliable prediction of post-treatment
recovery of spermatogenesis are available.
The strength of this study is the utilization of large register data, which made it possible to
estimate malformation risk in children conceived prior to as well as after TGCC diagnoses.
Through linking the national registries with SWENOTECA, we had access to complete and
detailed treatment data.
This study also had several limitations. Data on seminoma patients are lacking for the
period 1995–2000. However, misclassification due to inclusion of children of those men in the
control group should rather lead to diminishing the difference in malformation risk between
TGCC offspring and the non-TGCC offspring. Furthermore, despite the use of national regis-
tries, the number of children with malformations fathered by men who received radiotherapy
or very intensive chemotherapy treatment was still rather low. Therefore, the results for these
subgroups should be taken with some caution. Another limitation is the lack of data regarding
children born after insemination with cryopreserved or donor sperm. This was mitigated
through the sensitivity analysis in which children born after assisted reproduction were
excluded, which showed the same result.
To summarize, in this study comprising more than 2 million children, we found a slightly
increased risk of CMs in children fathered by men diagnosed with TGCC. The magnitude of
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the risk was similar in those conceived prior to as well as post-paternal–cancer therapy, indi-
cating no additional risk increase caused by radio- or chemotherapy.
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